This “HER2 Negative Breast Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2 Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ...
is HER2-negative, and has spread or cannot be removed by surgery (advanced gastric cancer). a kind of cancer called esophageal or certain gastroesophageal junction (GEJ) carcinomas that cannot be cured by surgery or a combination of chemotherapy and radiation therapy. It may be used with platin...
Most patients with hormone receptor (HR)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer can be cured by surgery and endocrine therapy, but a significant proportion suffer recurrences. Actinin-4 is associated with cancer invasion and metastasis, and its genetic...
SHR-1701, a PD-L1 and TGF-ß targeting agent, reduced chemotherapy-induced myelosuppression in patients with HER2-negative gastric/GEJ adenocarcinoma. Stomach cancer, gastric cancer, symptoms, stages, treatment, 3d illustration: © Crystal Light - stock.adobe.com ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Alpelisib(Piqray) is a P13K inhibitor in pill form that can be used with fulvestrant in women with advanced HR+, HER2-negative breast cancer with a PIK3CA gene mutation. Sacituzumab govitecan(Trodelvy) is a monoclonal antibody with an attached chemotherapy drug. It is used to treat some adva...
[23]. However, pivotal trials including phase III CHECKMATE-649 and ATTRACTION-4 trial demonstrated an efficacy of combination therapy with ICI and chemotherapy in first-line treatment, making this combination therapy an essential treatment option in HER2-negative advanced gastric cancer. Reinduction ...
et al. Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer. Breast Cancer Res 27, 3 (2025). https://doi.org/10.1186/s13058-024-01952-0 Download citation Published07 January ...
REVIEW Bevacizumab in the treatment of HER2-negative breast cancer Vito Lorusso Oncologic Institute,Vito Fazzi Hospital, Lecce, Italy Correspondence: Vito Lorusso P.zza Muratore, 1-73100 Lecce, Italy Tel/Fax +39 0832 661962 Email vitolorusso@inwind.it Abstract: Angiogenesis has a clear and ...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...